Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Non-Current Assets (2016 - 2026)

Cumberland Pharmaceuticals' Other Non-Current Assets history spans 16 years, with the latest figure at $3.0 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 6.8% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 6.8% increase, with the full-year FY2025 number at $3.0 million, up 6.8% from a year prior.
  • Other Non-Current Assets hit $3.0 million in Q4 2025 for Cumberland Pharmaceuticals, roughly flat from $3.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for CPIX hit a ceiling of $3.5 million in Q2 2021 and a floor of $2.4 million in Q3 2022.
  • Historically, Other Non-Current Assets has averaged $2.9 million across 5 years, with a median of $2.8 million in 2024.
  • Biggest five-year swings in Other Non-Current Assets: soared 368.94% in 2021 and later decreased 27.34% in 2022.
  • Tracing CPIX's Other Non-Current Assets over 5 years: stood at $3.4 million in 2021, then fell by 26.29% to $2.5 million in 2022, then grew by 6.83% to $2.7 million in 2023, then rose by 3.38% to $2.8 million in 2024, then rose by 6.8% to $3.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CPIX at $3.0 million in Q4 2025, $3.0 million in Q3 2025, and $2.9 million in Q2 2025.